Comparison
While Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880, MOTS-c improves insulin sensitivity, enhances glycolysis, reduces oxidative stress, and shows protective effects in models of metabolic syndrome, aging, and ischemia-reperfusion injury8135146.
While Liraglutide works as a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880, MOTS-c is a 16-amino-acid mitochondrial-derived peptide that translocates to the nucleus under metabolic stress and regulates glucose and lipid metabolism largely via activation of AMPK and modulation of mTOR and folate-cycle–linked pathways854140146.
Liraglutide is 31 amino acids long, whereas MOTS-c is shorter as it has a length of 16 amino acids. Liraglutide is made up of a sequence of sequence data not available in the current dataset. MOTS-c is made up of a sequence of Methionine, Arginine, Tryptophan, Glutamine, Glutamic acid, Methionine, Glycine, Tyrosine, Isoleucine, Phenylalanine, Tyrosine, Proline, Arginine, Lysine, Leucine, Arginine.
Liraglutide
GCG
MOTS-c
MT-RNR1